- Home
- STNG vs IBRX Comparison
STNG vs IBRX Comparison
Compare STNG & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STNG | IBRX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.3B |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | STNG | IBRX |
|---|---|---|
| Price | $51.51 | $2.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $69.20 | $9.71 |
| AVG Volume (30 Days) | 1.1M | ★ 14.9M |
| Earning Date | 02-11-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.88 | N/A |
| Revenue | ★ $889,539,000.00 | $82,555,000.00 |
| Revenue This Year | N/A | $667.18 |
| Revenue Next Year | $1.05 | $93.03 |
| P/E Ratio | $8.68 | ★ N/A |
| Revenue Growth | N/A | ★ 1025.95 |
| 52 Week Low | $30.63 | $1.83 |
| 52 Week High | $65.52 | $4.27 |
Technical Indicators
Market Signals| Indicator | STNG | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.92 | 47.16 |
| Support Level | $50.40 | $2.07 |
| Resistance Level | $51.95 | $2.29 |
| Average True Range (ATR) | 1.13 | 0.13 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 15.30 | 27.00 |
Price Performance
Historical ComparisonAbout STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.